Phaseline

Companies › Coya Therapeutics

Coya Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
COYA 302
Low-dose IL-2 to enhance regulatory T cell function combined with abatacept (CTLA-4 Ig) to
IL2, CD80, CD86Phase 2Amyotrophic Lateral Sclerosis (ALS)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07161999COYA 302Phase 2Amyotrophic Lateral Sclerosis (ALS)NeurologyApr 2027

From the company's SEC filings

Cash of $36m on 2026-09-30; operating cash outflow about $28m a year; runway about 15 months at that burn, to Jan 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

IL2 (1) CD80 (1) CD86 (1)

Companies with the same targets

Bristol-Myers Squibb Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics Synthekine Nektar Therapeutics HCW Biologics Asher Biotherapeutics Regeneron Pharmaceuticals Salspera

Companies built like this

Satellos Bioscience PepGen Cognition Therapeutics DiaMedica Therapeutics IGC Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.